Skip to main content

Table 1 Clinical characteristics of TNBC patients according to expression of PDGFRβ and CDCP1

From: The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer

  Overall cohort
(N = 65b)
PDGFRβ pos
(N = 29b)
PDGFRβ neg
(N = 36b)
P valuec CDCP1 pos
(N = 37b)
CDCP1 neg
(N = 28b)
P valuec
Age
 > = 50 years 42 (64.6%) 13 (44.8%) 29 (80.6%) 0,0040 22 (59.5%) 20 (71.4%) 0.4332
 < 50 years 23 (35.4%) 16 (55.2%) 7 (19.4%)   15 (40.5%) 8 (28.6%)  
Grade
 I, II 9 (14.1%) 0 (0%) 9 (25.7%) 0,0029 5 (13.5%) 4 (14.8%) 1.0000
 III 55 (85.9%) 29 (100.0%) 26 (74.3%)   32 (86.5%) 23 (85.2%)  
 na 1   1    1  
Necrosis
 No 14 (22.2%) 6 (20.7%) 8 (23.5%) 1,0000 6 (16.7%) 8 (29.6%) 0.2395
 Yes 49 (77.8%) 23 (79.3%) 26 (76.5%)   30 (83.3%) 19 (70.4%)  
 na 2   2   1 1  
Multifocality
 No 52 (82.5%) 24 (82.8%) 28 (84.4%) 1,0000 28 (77.8%) 24 (88.9%) 0.3255
 Yes 11 (17.5%) 5 (17.2%) 6 (17.6%)   8 (22.2%) 3 (11.1%)  
 na 2   2   1 1  
N positivity
 No 38 (58.5%) 17 (58.6%) 21 (58.3%) 1,0000 19 (51.4%) 19 (67.9%) 0.2117
 Yes 27 (41.5%) 12 (41.4%) 15 (41.7%)   18 (48.6%) 9 (32.1%)  
Size
 > 2 cm 39 (60.9%) 11 (39.3%) 15 (41.7%) 0,8035 15 (40.5%) 10 (37.0%) 0.8015
 < = 2 cm 25 (39.1%) 18 (64.3%) 21 (58.3%)   22 (59.5%) 17 (63.0%)  
 na 1 1     1  
DCISa
 No 40 (63.5%) 20 (68.9%) 20 (58.9%) 0,4424 23 (63.9%) 17 (63.0%) 1.0000
 Yes 23 (36.5%) 9 (31.0%) 14 (41.2%)   13 (36.1%) 10 (37.0%)  
 na 2   2   1 1  
  1. aDCIS, ductal carcinoma in situ
  2. bFrequency percentages were calculated on available cases
  3. cFisher’s exact test